BCL6 and non-small cell lung carcinoma: BCL6 is reportedly upregulated in glioblastoma and gastric, ovarian, and non-small cell lung cancers, and its expression is associated with malignant features, including proliferation, invasivity, migratory activity, survival, and therapeutic resistance (55).